Department of Dermatology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
Department of Orthopedics, the First People's Hospital of Jingzhou, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
J Mycol Med. 2023 Nov;33(4):101417. doi: 10.1016/j.mycmed.2023.101417. Epub 2023 Jul 23.
Candida infections of orthopedic implants are one of the most detrimental orthopedic implant-related complications with unsuccessful treatment and a poor prognosis. Most orthopedic Candida infections form biofilms and have resistance to the commonly used antifungal agents. This study aimed to develop a novel combination of normally prescribed drugs against Candida biofilm on orthopedic implants.
We cultured 26 clinical isolates of Candida strains to form biofilm without titanium sheets or on titanium sheets, which are the most commonly used materials for permanent or orthopedic implants. The checkerboard method was used to evaluate the synergistic effects of chlorhexidine (CHL) and azoles on these Candida biofilms. For the evaluation of synergistic effects, we constructed the cell viability assay by fluorescence staining and CFU reduction hot map of Candida.
Twenty-six clinical isolates of Candida strains formed biofilm in 96-well plates without titanium sheets, and we selected 9 of them to form biofilm on titanium sheets in 24-well plates. In Candida biofilm formed in 96-wells, the synergistic rates of CHL with fluconazole, itraconazole, and voriconazole were 61% (16/26), 65% (17/26), and 23% (6/26), respectively. When compared to the blank control group, CHL monotherapy significantly inhibited biofilm formation on titanium sheets (P < 0.05). We demonstrated 100% synergistic rates of the CHL and fluconazole combination against Candida biofilm formation on titanium sheets, and the minimum inhibitory concentration of CHL and FLU decreased four- to eight-fold.
We concluded that CHL combined with azoles inhibited the Candida biofilm formation 96-wells or on titanium sheets and has the potential to control the infections of orthopedic implants.
骨科植入物的念珠菌感染是最具破坏性的骨科植入物相关并发症之一,治疗效果不佳,预后不良。大多数骨科念珠菌感染形成生物膜,对常用抗真菌药物具有耐药性。本研究旨在开发一种针对骨科植入物上念珠菌生物膜的新型联合常规药物。
我们在没有钛片或钛片上培养了 26 株临床分离的念珠菌菌株,以形成生物膜,钛片是最常用于永久性或骨科植入物的材料。棋盘法用于评估洗必泰(CHL)和唑类药物对这些念珠菌生物膜的协同作用。为了评估协同作用,我们通过荧光染色构建了细胞活力测定法,并绘制了念珠菌的 CFU 减少热图。
26 株临床分离的念珠菌菌株在无钛片的 96 孔板中形成生物膜,我们选择其中的 9 株在 24 孔板的钛片上形成生物膜。在 96 孔中的念珠菌生物膜中,CHL 与氟康唑、伊曲康唑和伏立康唑的协同率分别为 61%(16/26)、65%(17/26)和 23%(6/26)。与空白对照组相比,CHL 单药治疗显著抑制了钛片上生物膜的形成(P<0.05)。我们证明了 CHL 和氟康唑联合治疗对钛片上念珠菌生物膜形成的协同率为 100%,并且 CHL 和 FLU 的最低抑菌浓度降低了四到八倍。
我们得出结论,CHL 联合唑类药物抑制了 96 孔或钛片上念珠菌生物膜的形成,具有控制骨科植入物感染的潜力。